May 14, 2021

Psychedelic Stock to Cure Obesity Epidemic? NeonMind BioSciences (NEON)

Midas Letter
Midas Letter
Psychedelic Stock to Cure Obesity Epidemic? NeonMind BioSciences (NEON)

NeonMind Biosciences Inc (CNSX:NEON, OTCMKTS:NMDBF) is a drug development organization focused on advancing psychedelic substances. The different angle NeonMind is taking from its “Magic Mushroom” competitors is how psychedelic substances can affect and help weight management to cure the obesity epidemic.

NeonMind is still an early-stage/preclinical data company. Still, they are focused on following companies like COMPASS Pathways PLC (NASDAQ:CMPS) in pursuing rigorous clinical trials to get applications in front of the FDA or Health Canada to have their substances approved as medicines.

“The only way to really advance these substance and get psychedelic substances into the mainstream for patients at large is to actually do the clinical trials, demonstrate safety and efficacy, put those files in front of a regulator and have them approve the medication” – Neonmind Biosciences CEO Robert Tessarolo

It has been proven that psychedelic compounds can have a profound effect on how a person perceives themselves. With further evidence that psychotherapy can also play an important role in helping patients suffering from obesity, NeonMind has two separate programs dedicated to helping those patients suffering. One high dose program used in conjunction with psychotherapy and one lower dose non-hallucinogenic pharmacotherapy prescribed medicine program.

NeonMind also markets wellness products with mushroom-infused functional foods such as coffee. The company plans to launch dietary supplements in the US in the next 6 months.

Watch the full interview to understand Neonmind’s business model, the people they are looking to help, and the company’s timeline to FDA approval and revenue generation.

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.